[exit] Penchant Research Library [3D]
Back to Search

ASP4345
B-

Primary Mechanism D1 PAM
Class Nootropic
Drug Status Phase 1
Alternate Names ASP-4345
Pubchem ID None/Unknown
Contributors @arche

Pharmacology

ASP4345 is a Dopamine Receptor D1 PAM. It is noted as similar in effect to generic ADHD medications however with a cleaner profile.

The small molecule compound has been trialed in a Phase 1 study [1], and was generally well tolerated, but the treatment group had a notable increase in treatment-emergent adverse events (TEAEs), with 34 for the placebo group and 73 for the treatment (ASP4345) group [2].

ASP4345 being a D1 allosteric modulator, rather than agonist, avoids most of the issues related to dopamine agonism such as tolerance and habit formation.

"There were no AEs that led to withdrawal of ASP4345 and no deaths were reported throughout the duration of the study." [2]

It has been hypothesized previously that even though it is a PAM, it may disregulate the dlPFC "goldilocks zone", however in subjective testing this has been shown to not be the case.

Its effective dose has been noted at about ~50mg in human testing.

Sources

[ 1 ] Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies
[ 2 ] Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia

Related

No related nodes found